Johnson & Johnson JNJ

$283.52 +3.11 (1.11%)

Valuation

Market cap
675,924,480,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.49
P/E (forward)
25.38
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,804,700
Avg volume
7,213,832
Day's range
$281.00 – $286.08
Shares out
2,407,310,000
Stochastic %K
84%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

M17K Nov 12, 10:16 PM
$SLS we are poised to explode on good results. - 57.1M short - Very low volume pin at the $8-9 range - Money staying on the sidelines for REGAL (but will likely pile in after either way) - Large Jan 2027 call volume ✅ If we get good results (yes it’s still “if” until it happens, don’t come at me toxic bulls) ➡️ Then we are poised to get T1 halt, along with a potentially large squeeze, along with new buys, along with more exercised calls and possibly an early Buyout notice. Whew. This next month through EOY will be HUGE. Place your bets. 💰 $MRK $JNJ
0 replies
openclassaction2 Nov 12, 10:02 PM
$JNJ 68,029 talc cases were pending in mdl 2738 as of june 1, per open class actions. lawsuit stage, no nationwide settlement, nothing to claim. seems like legacy bills outlast growth stories
0 replies
theoptionsplug Nov 12, 8:03 PM
So will $JNJ just forever keep going up?! Looking to see a break under $282 for put entry towards ~$275 then $262.45
0 replies
parcha Nov 12, 6:54 PM
https://youtube.com/watch?v=iJXFBhrYgSQ&is=uFaSsYobjmeQ1Y8o $AAPL $JNJ
0 replies
GettnFibbywIT Nov 12, 6:26 PM
$JNJ $XLV $IHE JNJ - Weekly Chart The "bull flag" pattern is often ( though not always) a continuation formation. A commonly used measured-move technique among discretionary traders is to add the length of the flagpole to the breakout level of the flag. Applying that framework here suggests a "potential" longer-term upside objective in the $340 -$345 ish range, based on an approximately 100-point flagpole advance added to the $240 breakout area. Measured-move targets should always be viewed as guideline objectives rather than forecasts and should be approached with appropriate risk management. However, JNJ's successful retest and acceptance of former resistance levels near $263 and $270, combined with constructive weekly momentum, reinforces confidence that the broader uptrend remains intact and that buyers continue to defend higher price levels.
0 replies
DollarFlipper Nov 12, 6:06 PM
$QQQ shorting the entire market except Healthcare. Added $BSX new position $JNJ shorting $SPY and qqq
1 replies
Stocktwits52wHighs Nov 12, 4:46 PM
$JNJ printed a new 52-week high today
0 replies
UnMaker Nov 12, 4:22 PM
$BB Do I need to tag all partners? $JNJ $XPEV $MSFT $LCID
0 replies